首页
关于我们
公司简介
技术平台
公司荣誉
发展历程
管理团队
产品中心
心血管介入
外周血管介入
神经介入
非血管介入
下载专区
新闻资讯
公司新闻
行业资讯
学术论文
加入我们
公司环境
员工发展
招聘岗位
联系我们
联系方式
在线留言
EN
1-year outcomes with the Absorb bioresorbable scaff old in patients with coronary artery disease: a patient-level, pooled meta-analysis
Background Compared with metallic drug-eluting stents, bioresorbable vascular scaffolds (BVS) offer the potential to improve long-term outcomes of percutaneous coronary intervention. Whether or not these devices are as safe and effective as drug-eluting stents within the first year after implantation is unknown.
2016
08-12
First-in-man Implantation of the XINSORB Bioresorbable Sirolimus-eluting Scaffold in China
To the Editor: A 35-year-old man who smoked for 15 years suffered from chest pain 12 days ago before admission. He was diagnosed as myocardial infarction. Thrombolytic therapy was given consequently. The electrocardiogram showed sub-acute inferior wall myocardial infarction. Echocardiogram showed attenuated constriction of the inferior wall with an ejection fraction of 59%. On September 5, 2013, he was treated with a XINSORB scaffold in right coronary artery (RCA).
Midterm results of endovascular treatment of superficial femoral artery disease with biodegradable stents:single-center experience
To assess the midterm efficacy of a biodegradable poly-l-lactic acid (PLLA) stent in the treatment of superficial femoral artery (SFA) occlusive disease.
Everolimus-Eluting Bioresorbable Scaffolds for Coronary Artery Disease
In patients with coronary artery disease who receive metallic drug-eluting coronary stents, adverse events such as late target-lesion failure may be related in part to the persistent presence of the metallic stent frame in the coronary-vessel wall. Bioresorbable vascularscaffolds have been developed to attempt to improve long-term outcomes.
Bioresorbable vascular scaffold implantation in acute coronary syndromes: clinical evidence, tips and tricks
Percutaneous coronary intervention (PCI) with a drug-eluting stent (DES) is routine treatment for patients with acute coronary syndromes (ACS). However, permanent metallic caging of the vessel has several shortcomings, such as side branch jailing and impossibility of late lumen enlargement.
A bioresorbable everolimus-eluting scaff old versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II)...
Background Despite rapid dissemination of an everolimus-eluting bioresorbable scaffold for treatment for coronary artery disease, no data from comparisons with its metallic stent counterpart are available. In a randomised controlled trial we aimed to compare an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent. Here we report secondary clinical and procedural outcomes after 1 year of follow-up.
Evaluation of the Biodegradable Peripheral Igaki-Tamai Stent in the Treatment
This study sought to evaluate the safety and performance of the Igaki-Tamai (Igaki Medical Planning Company, Kyoto, Janpan) biodegradable stent in patients with occlusive superficial femoral artery (SFA) disease.
新型钴铬合金可降解涂层西罗莫司洗脱支架在猪冠状动脉过度扩张模型中对新生内膜的影响
评价L-605 钴铬合金支架平台、聚丙交酯- 乙交酯(PLGA)共聚物载体西罗莫司药物洗脱支架在小型猪冠状动脉过度扩张模型中的安全性和有效性。
Stent thrombosis with drug-eluting stents: is the paradigm shifting?
First-generation drug-eluting stents (DES), which impart the controlled release of sirolimus or paclitaxel from durable polymers to the vessel wall, have been consistently shown to reduce the risk of restenosis and target vessel revascularization compared with bare metal stents (BMS).
Nine-month angiographic and two-year clinical follow-up of polymer-free sirolimus-eluting stent versus durable-polymer sirolimus-eluting stent for coronary artery disease: the Nano randomized trial
First generation drug-eluting stents (DES) were associated with a high incidence of late stent thrombosis (ST), mainly due to delayed healing and re-endothelization by the durable polymer coating. This study sought to assess the safety and efficacy of the Nano polymer-free sirolimus-eluting stent (SES) in the treatment of patients with de novo coronary artery lesions.
